Moreover, in HCC, we found most extrahepatic metastatic sites (except bone) showed a higher uptake of tracer than the liver (with a TLR of 3.6 ± 2.1), indicating [177Lu]Lu-PSMA-617 may be a useful treatment. Here, FOLH1 is linked to hepatocellular carcinoma.